Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Isovorin · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Isovorin | DRUG | - |
| UFT | DRUG | - |
| TS-1 | DRUG | - |
Inclusion Criteria: * Dukes C, Cure A colon cancer diagnosed histologically or cytologically * Normal organ function of bone marrow, heart, liver and kidney * Age 20-75 Other inclusion applies Exclusion Criteria: * Serious bone marrow suppression, infection, heart disease or complication * Famil...
Isovorin is an investigational small molecule being studied for the treatment of colon cancer and gastric cancer. It is being developed by Pfizer, Inc. (NYSE: PFE) and is currently in Phase 3 clinical development for these oncology indications.
Isovorin is a small molecule therapeutic being developed for oncology indications. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being evaluated for its potential efficacy in treating colon cancer and gastric cancer.
Isovorin is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with colon cancer and gastric cancer.
Isovorin is in Phase 3 clinical development. Two Phase 3 trials have been completed, one in gastric cancer and one in colon cancer. The drug is investigational and has not been approved by regulatory authorities for any indication.
Isovorin has been studied in two completed Phase 3 clinical trials. NCT00195572 evaluated the drug in advanced or recurrent gastric cancer with 200 participants in Japan. NCT00195585 evaluated the drug in colon cancer with 650 participants in Japan. Both trials enrolled adults aged 20 years and older.
Isovorin is a distinct drug product being developed by Pfizer. While it is a folate-based compound used in cancer treatment, its specific chemical identity and relationship to other folate derivatives have not been detailed in the clinical trial information available.